evidencegaps
Primary study · included by 1 review

Metformin and risk of cancer among patients with type 2 diabetes mellitus: A systematic review and meta-analysis.

Zhang 2021b · Zhang Kui, Bai Peng, Dai Hao, et al. · Primary care diabetes · 2021

Included by

Bladder cancer risk factors: a comprehensive umbrella review of meta-analyses.
Non-Cochrane · aetiology · 2026 · cited as Zhang 2021 · Table 1 (Included MA); References
Outcome this study informsPooled effectEvidenceCertainty
Risk of bladder cancer
With insulin glargine vs Without insulin glargine
OR 0.6 [0.37, 0.99]4 studies · 75702 participantsVery low
Risk of bladder cancer
With metformin vs Without metformin
OR 0.76 [0.63, 0.91]3 studies · 465588 participantsVery low

1 including review in total.